Charles Baltic

Amyndas Pharmaceuticals LLC is an American clinical-stage biopharmaceutical company that focuses on developing advanced complement therapies to treat inflammatory disorders in areas of unmet medical need. The private company has a robust R & D complement program with a diversified pipeline of C3 complement inhibitors. The company's priority clinical programs focus on kidney transplantation, PNH, C3G, periodontitis, AMD, and cancer immunotherapy. The company's lead candidates are recognized by the scientific community as the best C3-based complement inhibitors currently in development. Charles V. Baltic has been the CEO of the company since 2021.

Sidis Corp provides investment services for market-leading life science companies.

Needham & Co. LLC (Needham) is a registered investment advisor and broker/dealer headquartered in New York City. The firm was founded in 1985 and is a wholly-owned indirect subsidiary of The Needham Group, Inc. Needham provides corporate and institutional clients with high quality research, corporate access, capital markets and trading execution services in both the public and private markets, with an emphasis on growth companies.

The Hope Funds for Cancer Research provides funds for cancer research. The private company is based in Newport, RI. The company was founded by Leah Rush Cann.